Study of KN026 Monotherapy or Combined With Chemotherapy in Patients With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer Interventions: Drug: KN026 combination; Drug: KN026 monotherapy Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials